According to GlobalData’s company profile on Novartis, Cancer treatment biomarkers was a key innovation area identified from patents. Novartis's grant share as of January 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

Combination therapy for b-cell lymphoma with cd19 car and bcl2 inhibitor

The patent application (Publication Number: US20240033358A1) describes a method for treating B-cell lymphoma in a subject with increased levels of MYC gene or anti-apoptotic gene by administering a therapy involving immune effector cells expressing a Chimeric Antigen Receptor (CAR) that binds to CD19 along with a BCL2 inhibitor. This combination therapy aims to effectively treat B-cell lymphoma in subjects who may not have responded adequately to CD19 CAR therapy alone.

Furthermore, the patent application details methods for treating relapsed or refractory B-cell lymphoma by administering a BCL2 inhibitor to subjects who have not responded well to CD19 CAR therapy. The application also outlines specific criteria for identifying subjects with MYC-positive lymphomas and the use of BCL2 inhibitors in combination with CD19 CAR therapy. The disclosed methods cover various types of B-cell lymphomas, including high-grade B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma, providing a comprehensive approach to treating these conditions. Additionally, the patent application emphasizes the importance of evaluating subjects for genetic alterations before and during treatment to optimize therapeutic outcomes.

To know more about GlobalData’s detailed insights on Novartis, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

Be better informed